PALI · Palisade Bio, Inc.
$1.57
+0.12 (+7.93%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$252.69M
Shares
174.27M
Volume · Oct 9
658.54K
Avg daily vol (3M)
2.6M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.45
Open$1.47
Day$1.38–1.48
52W close$1.35–2.80
Avg vol 30d3.2M
Short int30.3M · 17.4% float · 13.8d
Short vol44%
DataJan 2020–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$500,000
Trailing 12 months
Net income (TTM)
−$31.94M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-7,069.8%
Trailing 12 months
P / E (TTM)
2.2
Trailing earnings · reciprocal yield 44.8%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4,306.4%
Year over year · more shares
Price change (1Y)
-27.5%
Trailing year
Short interest
17.4%
Latest settlement · 13.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−23%
below
RSI (14)
36
neutral
MACD trend
Positive
52-week position
7%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−40%
trailing
YTD return
−38%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
2 of 124 funds reported for Sep 30 · net +4.7K sh shares · +2 new
Insider flow
Accumulating
Net +$28.8K over 90 days · 0% sells
Short interest
Falling
17.37% of float · ▼ -2.1% MoM · 13.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
124 holders — near 3-yr high, broad support
Squeeze score
70
high risk · 0–100
Fundamentals
Revenue growth
+1500%
Y/Y
EPS growth
+97%
Y/Y
Free cash flow
$-10.8M
Balance sheet
$10.4M
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−23%
Bearish
RSI (14)
36
Neutral
MACD trend
Positive
Bullish
52-week position
7%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
2 of 124 funds reported for Sep 30 · net +4.7K sh shares · +2 new
Insider flow
Accumulating
Net +$28.8K over 90 days · 0% sells
Short interest
Falling
17.37% of float · ▼ -2.1% MoM · 13.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
124 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 7%
Range high $3
vs 200-day avg -24%
vs 50-day avg -23%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PALI
this stock
Palisade Bio, Inc.
|
$252.69M | -38.3% | +1500.4% | — | 17.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +11.0% | +46.2% | 29.3 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PALI | +1.4% | -27.9% | -39.6% | +7.4% | -38.3% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | +0.1% | -30.0% | -48.6% | +5.9% | -51.8% |